The present invention provides fermented milk having a high angiotensin converting enzyme inhibition activity, a high hypotensive activity and/or a high stroke-preventing activity. The present invention also provides a method for producing fermented milk having a high angiotensin converting enzyme inhibition activity, a high hypotensive activity and/or a high stroke-preventing activity and a method for producing Tyr-Pro, each of which is characterized by comprising fermenting milk with a mushroom.

Provided is a purified chlorogenic acid-containing composition, having: a content of a chlorogenic acid in solids of from 10 mass % to 70 mass %; a glucose/chlorogenic acid mass ratio of from 0.1 to 0.9; a caffeine/chlorogenic acid mass ratio of 0.05 or less; and a pH of from 1 to 5.

A dough- or batter-based food product is prepared by mixing dough or batter ingredients to establish a dough or batter composition, the dough ingredients including at least flour, water and salt. The salt particles have dissolution rate of at least 120 seconds. Batter or dough provided herein, and cooked foods made from the batter or dough, include pockets of salt at a higher concentration than the dough, batter, or cooked food overall. Batter- or dough-based food products provided have a saltiness perception level substantially the same as compared to batter- or dough-based food products that include table salt in an amount at least 40% greater than the provided batter- or dough-based food product.

The present invention provides a reducing cholesterol probiotic strain, composition thereof and use thereof. The probiotic strain is Lactobacillus plantarum, which itself and its metabolites can effectively reduce the cholesterol content, enhance the gene expression level of SCARB1, APOA1, and LDLR to promote the effect of cholesterol metabolism, and can effectively reduce the total cholesterol and the low-density lipoprotein in human blood.

The present invention provides a reducing cholesterol probiotic strain, composition thereof and use thereof. The probiotic strain is Lactobacillus plantarum, which itself and its metabolites can effectively reduce the cholesterol content, enhance the gene expression level of SCARB1, APOA1, and LDLR to promote the effect of cholesterol metabolism, and can effectively reduce the total cholesterol and the low-density lipoprotein in human blood.

Novel compositions comprising omega-3 fatty acids and uses thereof are disclosed.

Novel compositions comprising omega-3 fatty acids and uses thereof are disclosed.

Compositions comprising from about 40 weight parts to about 1000 weight parts of a botanical nitrate source; from about 20 weight parts to about 500 weight parts of a botanical source of nitrite reduction activity; and from about 4 weight parts to about 100 weight parts of a nitrite salt. Use of said composition in methods of reducing triglycerides or reducing C-reactive protein levels are also provided.

Compositions comprising from about 40 weight parts to about 1000 weight parts of a botanical nitrate source; from about 20 weight parts to about 500 weight parts of a botanical source of nitrite reduction activity; and from about 4 weight parts to about 100 weight parts of a nitrite salt. Use of said composition in methods of reducing triglycerides or reducing C-reactive protein levels are also provided.

The presently disclosed subject matter is directed a system and method of creating personalized doses of active pharmaceutical ingredients (APIs) dispersed in a palatable oral formulation. The APIs are encapsulated into microparticles that are dispersed within a thixotropic suspension vehicle to create a customized oral formulation. The formulation can be customized for a particular subject based on medical condition, time release of the API, release profile of the API, and taste preference of the subject.